1. Vitamin D Related/Nuclear Receptor
  2. Estrogen Receptor/ERR
  3. Chrysin

Chrysin  (Synonyms: 5,7-Dihydroxyflavone)

Cat. No.: HY-14589 Purity: 99.85%
SDS COA Handling Instructions Technical Support

Chrysin is one of the most well known estrogen blockers.

For research use only. We do not sell to patients.

Chrysin Chemical Structure

Chrysin Chemical Structure

CAS No. : 480-40-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Chrysin:

Top Publications Citing Use of Products

View All Estrogen Receptor/ERR Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Chrysin is one of the most well known estrogen blockers.

IC50 & Target

estrogen

Cellular Effect
Cell Line Type Value Description References
2008 IC50
28.62 μM
Compound: 2, Chry
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-375 IC50
29.65 μM
Compound: 8
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
[PMID: 19782567]
A-375 IC50
33.23 μM
Compound: 2, Chry
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
29.39 μM
Compound: 2, Chry
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
60.13 μM
Compound: 2, Chry
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A549 IC50
> 1 x 10-4 M
Compound: 1
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
[PMID: 20619940]
A549 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
[PMID: 32160978]
A549 IC50
> 50 μM
Compound: Chrysin
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
[PMID: 31615696]
A549 IC50
19.88 μM
Compound: 8
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
[PMID: 19782567]
A549 EC50
233 μM
Compound: 3
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 12027739]
A549 IC50
28 μM
Compound: Chrysin
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 34171512]
A549 IC50
47.8 μM
Compound: Chrysin
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
[PMID: 30031652]
B16-BL6 EC50
74.4 μM
Compound: 3
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
[PMID: 12027739]
B16-F10 IC50
17.45 μM
Compound: Chrysin
Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
[PMID: 30031652]
BALB/3T3 IC50
248.2 μM
Compound: 2
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
[PMID: 10096863]
BXPC-3 IC50
54.27 μM
Compound: 2, Chry
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C13 IC50
49.66 μM
Compound: 2, Chry
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C8166 CC50
110 μg/mL
Compound: 5
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
[PMID: 24794743]
C8166 EC50
13.4 μg/mL
Compound: 5
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
[PMID: 24794743]
Caco-2 IC50
9.5 μM
Compound: 23
Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay
Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay
[PMID: 28793973]
DLD-1 IC50
18.62 μM
Compound: 4
Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
10.1039/C5MD00163C
DU-145 IC50
9.81 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay
Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay
10.1007/s00044-010-9395-1
H22 IC50
1671 μM
Compound: 1, Chrysin
Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay
Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay
[PMID: 24556144]
H9 IC50
47 μM
Compound: 11
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
[PMID: 8158164]
H9 EC50
5 μM
Compound: 11
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
[PMID: 8158164]
HCT-116 IC50
> 100 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay
Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay
10.1007/s00044-010-9395-1
HCT-15 IC50
54.43 μM
Compound: 2, Chry
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HEK293 IC50
77.45 μM
Compound: 2, Chry
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HEK-293T IC50
319.36 μM
Compound: Chrysin
Cytotoxicity against human 293T cells after 48 hrs by MTT assay
Cytotoxicity against human 293T cells after 48 hrs by MTT assay
[PMID: 30031652]
HeLa IC50
≥ 10 μM
Compound: chrysin
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 19278239]
HeLa EC50
111 μM
Compound: 3
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
[PMID: 12027739]
HeLa IC50
14.2 μM
Compound: Chrysin
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay
[PMID: 28797675]
HeLa IC50
2.9 x 10-5 M
Compound: 1
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
[PMID: 20619940]
HeLa IC50
25.05 μM
Compound: Chrysin
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
[PMID: 30031652]
HeLa IC50
43 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
10.1007/s00044-010-9395-1
HepG2 IC50
> 100 μM
Compound: Chrysin
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 26896708]
HepG2 IC50
16.5 μM
Compound: 4
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
10.1039/C5MD00163C
HL-60 IC50
33.98 μM
Compound: 8
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
[PMID: 19782567]
HT-1080 EC50
94.9 μM
Compound: 3
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
[PMID: 12027739]
HT-29 IC50
> 1 x 10-4 M
Compound: 1
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
[PMID: 20619940]
HT-29 IC50
19.49 μM
Compound: 4
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
10.1039/C5MD00163C
Huh-7 CC50
> 50 μM
Compound: 18
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
[PMID: 22445328]
Jurkat IC50
4.9 μM
Compound: Chrysin
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
[PMID: 30776692]
Jurkat IC50
6.1 μM
Compound: Chrysin
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
[PMID: 30776692]
K562 IC50
> 100 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay
Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay
10.1007/s00044-010-9395-1
K562 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
[PMID: 32160978]
K562 IC50
> 50 μM
Compound: Chrysin
Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
[PMID: 31615696]
KB IC50
29.6 μM
Compound: Chrysin
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 34171512]
KYSE-510 IC50
63 μM
Compound: Chrysin
Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay
Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay
[PMID: 28797675]
L02 IC50
> 100 μM
Compound: Chrysin
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
[PMID: 26896708]
MCF7 IC50
2.6 μM
Compound: 10
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
MCF7 IC50
25.66 μM
Compound: Chrysin
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 30031652]
MCF7 IC50
26.9 μM
Compound: Chrysin
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 34171512]
MCF7 IC50
50 nM
Compound: Chrysin
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
[PMID: 33257172]
MCF7 IC50
50.32 μM
Compound: 2, Chry
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
MCF7 GI50
69 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
10.1007/s00044-012-0423-1
MDA-MB-231 IC50
33 μM
Compound: Chrysin
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 34171512]
MDCK IC50
1.5 μM
Compound: 10
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
Mesenchymal stem cells EC50
77.7 μM
Compound: 1
Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay
Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay
[PMID: 37077388]
MOLT-4 GI50
58.6 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
10.1007/s00044-012-0423-1
Monocyte IC50
2.4 μM
Compound: chrysin
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
[PMID: 8882428]
MRC5 IC50
> 100 μM
Compound: 1
Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
[PMID: 32160978]
MRC5 IC50
> 100 μM
Compound: Chrysin
Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
[PMID: 31615696]
NCI/ADR-RES IC50
51.04 μM
Compound: 2, Chry
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
NCI-H1299 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
[PMID: 32160978]
NCI-H1299 IC50
> 50 μM
Compound: Chrysin
Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
[PMID: 31615696]
Neutrophil IC50
53 μM
Compound: 4a
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
[PMID: 23871908]
Neutrophil IC50
9.59 μM
Compound: 4a
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
[PMID: 23871908]
PC-3 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
[PMID: 32160978]
PC-3 IC50
> 50 μM
Compound: Chrysin
Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
[PMID: 31615696]
RBL-2H3 IC50
> 500 μM
Compound: 11
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
[PMID: 14510616]
RD EC50
15.89 μM
Compound: CR
Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay
Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay
[PMID: 27776325]
SGC-7901 IC50
> 100 μM
Compound: Chrysin
Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay
Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay
10.1007/s00044-010-9395-1
SW480 IC50
31.08 μM
Compound: 4
Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
10.1039/C5MD00163C
T-cell CC50
428.27 μM
Compound: 1, CR
Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay
Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay
[PMID: 21131104]
T-cell IC50
44.16 μM
Compound: 1, CR
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay
[PMID: 21131104]
THP-1 IC50
23.38 μM
Compound: 8
Cytotoxicity against human THP1 cells by MTT assay
Cytotoxicity against human THP1 cells by MTT assay
[PMID: 19782567]
In Vitro

Chrysin is mainly found in passion flowers, honey, and propolis acts as a potential therapeutic and preventive agent to inhibit proliferation and invasion of various human cancer cells. Although Chrysin has anti-carcinogenic effects in several cancers, little is known about its functional roles in ovarian cancer which shows poor prognosis and chemoresistance to traditional therapeutic agents. Chrysin inhibits ovarian cancer cell proliferation and induced cell death by increasing reactive oxygen species (ROS) production and cytoplasmic Ca2+ levels as well as inducing loss of mitochondrial membrane potential (MMP). Chrysin activates MAPK and PI3K/AKT pathways in ES2 and OV90 cells in concentration-response experiments. Chrysin suppresses tumor growth byregulating canonical Wnt and nuclear factor NF-κB signaling cascades cancer cells.? Chrysin stimulates the phosphorylation of AKT and P70S6K proteins in both ES2 and OV90 cells compared tothe untreated control cells.? In addition, Chrysin activates the phospho-ERK1/2, p38,and JNK proteins as members of the MAPK pathway in the ovarian cancer cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

254.24

Formula

C15H10O4

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (393.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.9333 mL 19.6665 mL 39.3329 mL
5 mM 0.7867 mL 3.9333 mL 7.8666 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 10 mg/mL (39.33 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.85%

References
Cell Assay
[1]

The proliferation assays are conducted using a cell proliferation enzyme-linked immunosorbent assay (ELISA) 5-bromo-2'-deoxyuridine (BrdU) kit. Briefly, ES2 and OV90 cells are seeded in a 96-well plate, and then treated with Chrysin (0, 5, 10, 20, 50, and 100 µM) with or without inhibitors (20 μM LY294002, PI3K/AKT; 10 μM U0126, ERK1/2; 10 μM SP600125, JNK; and 20 μM SB203580, p38) in a final volume of 100 μL/well. Aftera48-h incubation, 10 μM BrdU is added to the cell culture, followed by an additional 2-h incubation at 37°C. After labeling the cells with BrdU, they are fixed and then incubated with the anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to the BrdU incorporated into newly synthesized cellular DNA and these immune complexes are detected by analyzing their reaction with the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product are measured at 370 and 492 nm using an ELISA reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.9333 mL 19.6665 mL 39.3329 mL 98.3323 mL
5 mM 0.7867 mL 3.9333 mL 7.8666 mL 19.6665 mL
10 mM 0.3933 mL 1.9666 mL 3.9333 mL 9.8332 mL
15 mM 0.2622 mL 1.3111 mL 2.6222 mL 6.5555 mL
20 mM 0.1967 mL 0.9833 mL 1.9666 mL 4.9166 mL
25 mM 0.1573 mL 0.7867 mL 1.5733 mL 3.9333 mL
30 mM 0.1311 mL 0.6555 mL 1.3111 mL 3.2777 mL
40 mM 0.0983 mL 0.4917 mL 0.9833 mL 2.4583 mL
50 mM 0.0787 mL 0.3933 mL 0.7867 mL 1.9666 mL
60 mM 0.0656 mL 0.3278 mL 0.6555 mL 1.6389 mL
80 mM 0.0492 mL 0.2458 mL 0.4917 mL 1.2292 mL
100 mM 0.0393 mL 0.1967 mL 0.3933 mL 0.9833 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Chrysin
Cat. No.:
HY-14589
Quantity:
MCE Japan Authorized Agent: